During the quarter ended March 31, 2026, Baron Health Care Fund® (the Fund) declined 6.97% (Institutional Shares), compared ...

On May 22, Hangzhou Diagens Biotechnology Co., Ltd. announced that its proprietary AI AutoVision® Chromosome Karyotype ...

Discover a practical framework for evaluating healthcare stocks through pipeline strength, patent strategy, regulatory ...

STEMart announces the expansion of its analytical instrument catalog with a robust selection of Viscometer and ...

Quarter four revenue was $2,112.5 million. Full year revenue was $8,251 million. Quarter four adjusted EBITDA of $327.1 million or 15.5% of revenue; full year adjusted ...

Conexeu Sciences Inc. ("Conexeu" or the "Company") , a biotechnology company advancing tissue regeneration, today announced the launch of a preclinical development program for B.R.E.A.S.T.™ ...

For patients with rare diseases, finding a relevant clinical trial can be a difficult and fragmented process, but a new ...

ICON plc (NASDAQ: ICLR), a world-leading clinical research organization, today announced that it will release financial results for the fourth quarter and full year 2025 results after the market ...

Advances in medical technology mean we could live to be very old. Read more at straitstimes.com. Read more at ...

Up to $1.3 billion in flexible, non-dilutive capital, including up to $800 million of synthetic royalty and access of up to $500 million in senior corporate debt . Combined with c ...

Explore practical U.S. midcap portfolio strategies with diversification, sector balance, and long-term market exposure for ...

Another significant step towards the success of ICVAX®HONG KONG SAR – Media OutReach Newswire – 27 May 2026 – Immuno Cure Group (“Immuno Cure“), headquartered at Hong Kong Science Park, is pleased to ...